Concomitant THC and stress adolescent exposure induces impaired fear extinction and related neurobiological changes in adulthood

Resum

Δ9-tetrahydrocannabinol (THC) consumption during adolescence is reported to be a risk factor for the appearance of psychiatric disorders later in life. The interaction between genetic or environmental events and cannabinoid exposure in the adolescent period can also contribute to exacerbate behavioural deficits in adulthood. Here we investigate the effects of THC treatment as well as the consequences of concomitant THC and stress exposure during adolescence in the extinction of fear memory in adult mice. Adolescent mice treated with THC and exposed to stress exhibit impaired cued fear extinction in adulthood. However, no effect was observed in animals exposed to these two factors separately. Notably, resistance to fear extinction was associated with decreased neuronal activity in the basolateral amygdala (BLA) and the infralimbic prefrontal cortex, suggesting a long-term dysregulation of the fear circuit. These changes in neuronal activation were paralleled with structural plasticity alterations. Indeed, an increase of immature dendritic spines in pyramidal neurons of the BLA was revealed in mice simultaneously exposed to THC and stress. Corticosterone levels were also enhanced after the cued fear conditioning session in the same experimental group. These results show that an interaction between cannabis exposure and stress during adolescence may lead to long-term anxiety disorders characterized by the presence of pathological fear.


This work was supported by “Plan Nacional sobre Drogas” (#2014I019) and “Ministerio de Economía y Competitividad” (SAF2017-85299-R) to FB, the "Generalitat de Catalunya-AGAUR" (#2014-SGR-1547), ICREA-Acadèmia(2015) and “Ministerio de Economía y Competitividad” (#SAF2017-84060-R) to RM, NARSAD Young Investigator Grant #22434, Ramón y Cajal program RYC2014-15784, RETOS-MINECOSAF2016-76565-R and FEDER funds to RA, and “Ministerio de Economía y Competitividad” (SAF2014-53876R) and “Generalitat de Catalunya” (SGR 2014-1020) to AA

Tipus de document

Article


Versió acceptada

Llengua

Anglès

Publicat per

Elsevier

Documents relacionats

Neuropharmacology. 2019 Jan;144:345-57

info:eu-repo/grantAgreement/ES/1PE/SAF2017-85299-R

info:eu-repo/grantAgreement/ES/1PE/SAF2017-84060-R

info:eu-repo/grantAgreement/ES/1PE/SAF2016-76565-R

info:eu-repo/grantAgreement/ES/1PE/SAF2014-53876R

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

© Elsevier http://dx.doi.org/10.1016/j.neuropharm.2018.11.016

Aquest element apareix en la col·lecció o col·leccions següent(s)